Editorial

Professor Mohammad Barzegar-Jalali: Four Decades Scientific Efforts at Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.

Mohammad Reza Siahi, Alireza Garjani[*], Ali Shayanfar

Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.

Professor Mohammad Barzegar-Jalali was born on June 1945 in Ardabil, Iran. He received his Pharm.D from Tehran University of Medical Sciences (Tehran, Iran) in 1969 and PhD in pharmaceutics (1975 to 1979) from De Montfort University (Leicester, UK) with a dissertation entitled "studies on the bioavailability of drugs from peroral aqeous suspensions". He has worked as a full academic member at Faculty of Pharmacy, Tabriz University of Medical Sciences (TUOMS, Tabriz, Iran) from 1971, teaching physical pharmacy, pharmacokinetic, pharmacodynamic and biopharmacy to graduate and postgraduate students and has published more than 150 research and review articles in international peer-reviewed journals. Professor Barzegar-Jalali awarded two gold medals from the Iranian Razi Research Festival in 1996 and 2002 for his academic achievements. In 2015, he was appointed as the first distinguished professor of TUOMS and was selected as 1% of top scientist worldwide based on the Essential Science Indicators (ESI) ranking. His research field includes in the following issues: (a) formulation technologies for enhancing the solubility and dissolution of drugs and drug candidates including the use of nanotechnology and solid dispersions [1-5] (b) modeling of physicochemical and pharmacokinetic properties i.e. solubility prediction of drugs in solvent mixtures,[6,7] correlation between physicochemical properties and anesthetic potencies [8] in-vitro-in vivo correlation (IVIVC) of drug nanosystems parameters for prediction purposes,[9] modeling of drug release kinetic from nanoparticles,[10] (c) pharmacokinetic studies such as determination of drug bioavailability.[11,12]

This special edition of Pharmaceutical Sciences (PS) is published in honor of Professor Mohammad Barzegar-Jalali for his lifelong efforts toward pharmacy training and research. This issue includes original scientific papers in his research filed. Our best wishes and congratulation for his well deserved awards and scientific efforts.

Conflict of Interest

The authors report no conflicts of interest.

References

1. Barzegar-Jalali M, Maleki N, Garjani A, Khandar AA, Haji-Hosseinloo M, Jabbari R, et al. Enhancement of dissolution rate and anti-inflammatory effects of piroxicam using solvent deposition technique. *Drug Dev Ind Pharm* 2002;28:681-686. doi: 10.1081/DDC-120003859

2. Barzegar-Jalali M, Valizadeh H, Shadbad MRS, Adibkia K, Mohammadi G, Farahani A, et al. Cogrinding as an approach to enhance dissolution rate of a poorly water-soluble drug (gliclazide). *Powder Technol* 2010;197:150-158. doi: 10.1016/j.powtec.2009.09.008

3. Barzegar-Jalali M, Ghanbarzadeh S, Adibkia K, Valizadeh H, Bibak S, Mohammadi G, et al. Development and characterization of solid dispersion of piroxicam for improvement of dissolution rate using hydrophilic carriers. *Bioimpacts* 2014;4:141-148. 10.1016/j.powtec.2009.09.008

4. Barzegar-Jalali M, Alaei-Beirami M, Javadzadeh Y, Mohammadi G, Hamidi A, Andalib S, et al. Comparison of physicochemical characteristics and drug release of diclofenac sodium-eudragit® rs100 nanoparticles and solid dispersions. *Powder Technol* 2012;219:211-216. doi: 10.1016/j.powtec.2011.12.046

5. Dastmalchi S, Garjani A, Maleki N, Sheikhee G, Baghchevan V, Jafari-Azad P, et al. Enhancing dissolution, serum concentrations and hypoglycemic effect of glibenclamide using solvent

Corresponding Author: Alireza Garjani, Tel: (+98) 41 33341315 , Fax: (+98) 41 33344798, E-mail:garjania@tbzmed.ac.ir

deposition technique. *J Pharm Pharm Sci* 2005;8:175-181.

6. Barzegar-Jalali M, Hanaee J. Model for solubility estimation in mixed solvent systems. *Int J Pharm* 1994;109:291-295. doi: 10.1016/0378-5173(94)90391-3

7. Barzegar-Jalali M, Jouyban-Gharamaleki A. A general model from theoretical cosolvency models. *Int J Pharm* 1997;152:247-250. doi: 10.1016/S0378-5173(97)04922-3

8. Dastmalchi S, Barzegar-Jalali M. Relationship between potency and boiling point of general anesthetics: A thermodynamic consideration. *Int J Pharm* 2000;202:41-45.

9. Barzegar-Jalali M, Mohammadi K, Mohammadi G, Valizadeh H, Barzegar-Jalali A, Adibkia K, et al. A correlative model to predict in vivo auc for nanosystem drug delivery with release rate-limited absorption. *J Pharm Pharm Sci* 2012;15:583-591.

10. Barzegar-Jalali M, Adibkia K, Valizadeh H, Shadbad MRS, Nokhodchi A, Omidi Y, et al. Kinetic analysis of drug release from nanoparticles. *J Pharm Pharm Sci* 2008;11:167-177.

11. Barzegar-Jalali M. Determination of absolute drug bioavailability without intravenous administration by renal clearance perturbation using urinary excretion data. *Int J Pharm* 1980;5:253-255. doi: 10.1016/0378-5173(80)90132-5

12. Barzegar-Jalali M, Barzegar-Jalali A. Bioavailability determination for drugs exhibiting variable renal excretion rate constant between treatments. *Int J Pharm* 1995;120:111-114. doi: 10.1016/0378-5173(94)00422-2